An Exploratory Clinical Study on the Safety and Efficacy of Allogeneic CD19/BCMA CAR-T Cell Treatment for Relapsed/ Refractory B-cell or Plasma Cell-derived Malignant Tumors
Latest Information Update: 11 Jun 2025
At a glance
- Drugs RN-1101 (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Acronyms RunNing
Most Recent Events
- 04 Jun 2025 Planned initiation date changed from 20 May 2025 to 28 May 2025.
- 26 May 2025 New trial record